Immutep Ltd has released a press release.
Immutep Reports Positive Phase II TACTI-002 Data
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- Enrollment completed for the INSIGHT-004 Study
- Immutep March Quarterly Activities Report & Appendix 4C
- Immutep advances its LAG-3 agonist for autoimmune diseases
- Immutep presents TACTI-002 data at AACR Virtual Meeting
- EOC Pharma confirms plans to advance Efti in China for MBC
Later from Immutep
- Immutep Investor Presentation
- INSIGHT-004 and TACTI-002 data to be presented at ASCO
- Immutep granted Japanese patent for eftilagimod alpha
- Immutep receives $3.6M R&D French tax incentive
- Immutep announces improving data from TACTI-002 ph II trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep